340B Drug Pricing Program
Amicus Brief: ABBVIE INC., et al., v. Keith M. Ellison, in his official capacity as Attorney General of Minnesota Motion to Dismiss 340B Litigation
Amicus Brief: Motion to Dismiss in Astrazeneca Pharmaceuticals LP v Plaintiff, Attorney General of the State of Minnesota in 340B litigation.
The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program.
A Louisiana district court yesterday upheld a state law prohibiting drug companies from denying Louisiana hospitals 340B discounts for drugs dispensed at community pharmacies.
A Louisiana district court Sept. 30 upheld a state law prohibiting drug companies from denying Louisiana hospitals 340B discounts for drugs dispensed at community pharmacies.
Johnson & Johnson Sept. 30 notified the Health Resources and Services Administration that it is ceasing implementation of its proposed 340B rebate model.
As urged by the AHA and others, J&J tells HRSA it is abandoning proposed 340B rebate plan.
The Court held a consolidated hearing on the various motions on June 6, 2024. After oral arguments, the Court took all the motions under advisement.
The AHA is pleased that Johnson & Johnson has decided to cease implementation of its 340B rebate proposal, which would have harmed patients and 340B providers. We are especially appreciative of HRSA’s efforts to convince J&J to put an end to this unlawful proposal and those members of…
The Health Resources and Services Administration Sept. 27 sent a final warning letter to Johnson & Johnson urging the company to inform the agency by Monday, Sept. 30 that it would halt its proposed 340B rebate model scheduled to go into effect next month.